Compugen (CGEN)
(Delayed Data from NSDQ)
$1.75 USD
+0.03 (1.74%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $1.74 -0.01 (-0.57%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CGEN 1.75 +0.03(1.74%)
Will CGEN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEN
United Therapeutics (UTHR) Completes Enrolment in IPF Study
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
CGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
uniQure (QURE) Soars on New Huntington's Disease Study Data
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
Other News for CGEN
Compugen to Present at Upcoming Antibody Industrial Symposium
Compugen Earns Milestone from AstraZeneca Trial
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen to receive $5M milestone payment from AstraZeneca
Biotech Alert: Searches spiking for these stocks today